Sharon C. Cheetham

3.6k total citations
70 papers, 2.8k citations indexed

About

Sharon C. Cheetham is a scholar working on Cellular and Molecular Neuroscience, Molecular Biology and Pharmacology. According to data from OpenAlex, Sharon C. Cheetham has authored 70 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 45 papers in Cellular and Molecular Neuroscience, 26 papers in Molecular Biology and 24 papers in Pharmacology. Recurrent topics in Sharon C. Cheetham's work include Neuroscience and Neuropharmacology Research (28 papers), Neurotransmitter Receptor Influence on Behavior (27 papers) and Treatment of Major Depression (15 papers). Sharon C. Cheetham is often cited by papers focused on Neuroscience and Neuropharmacology Research (28 papers), Neurotransmitter Receptor Influence on Behavior (27 papers) and Treatment of Major Depression (15 papers). Sharon C. Cheetham collaborates with scholars based in United Kingdom, United States and Germany. Sharon C. Cheetham's co-authors include M. Rufus Crompton, Cornelius Katona, Roger W. Horton, David J. Heal, Freddy De Paermentier, Steven P. Vickers, Jean Viggers, Sharon L. Smith, S P Vickers and M.R. Prow and has published in prestigious journals such as Diabetes, Biological Psychiatry and Brain Research.

In The Last Decade

Sharon C. Cheetham

70 papers receiving 2.7k citations

Peers

Countries citing papers authored by Sharon C. Cheetham

Since Specialization

Citations

This map shows the geographic impact of Sharon C. Cheetham's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sharon C. Cheetham with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sharon C. Cheetham more than expected).

Fields of papers citing papers by Sharon C. Cheetham

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sharon C. Cheetham. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sharon C. Cheetham. The network helps show where Sharon C. Cheetham may publish in the future.

Co-authorship network of co-authors of Sharon C. Cheetham

This figure shows the co-authorship network connecting the top 25 collaborators of Sharon C. Cheetham. A scholar is included among the top collaborators of Sharon C. Cheetham based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sharon C. Cheetham. Sharon C. Cheetham is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Effects of corticosterone within the hypothalamic arcuate nucleus on food intake and body weight in male rats 2020 ·Molecular Metabolism ·Chioma Izzi‐Engbeaya, Yue Ma, (unknown), Risheka Ratnasabapathy, (unknown), John R. Counsell, (unknown), (unknown), (unknown), (unknown), (unknown), Sharon C. Cheetham, Jonathan R. Seckl, Kevin G. Murphy, Waljit S. Dhillo, James Gardiner	10
2	A sustained release formulation of novel quininib-hyaluronan microneedles inhibits angiogenesis and retinal vascular permeability in vivo 2016 ·Journal of Controlled Release ·Orla Galvin, Akshay Srivastava, Oliver Carroll, (unknown), (unknown), Steven P. Vickers, Keith Dickinson, Alison Reynolds, (unknown), Gareth Redmond, (unknown), Sharon C. Cheetham, Abhay Pandit, Breandán N. Kennedy	28
3	Metabolic Consequences of Antipsychotic Therapy: Preclinical and Clinical Perspectives on Diabetes, Diabetic Ketoacidosis, and Obesity 2012 ·Handbook of experimental pharmacology ·David J. Heal, Jane Gosden, Helen C. Jackson, Sharon C. Cheetham, Sharon L. Smith	18
4	The utility of animal models to evaluate novel anti‐obesity agents 2011 ·British Journal of Pharmacology ·Steven P. Vickers, Helen C. Jackson, Sharon C. Cheetham	81
5	Synthesis and SAR of 4-aryl-1-(indazol-5-yl)pyridin-2(1H)ones as MCH-1 antagonists for the treatment of obesity 2010 ·Bioorganic & Medicinal Chemistry Letters ·Mark Hadden, (unknown), Alan J. Henderson, M. D. Surman, (unknown), Yuri L. Khmelnitsky, Steven P. Vickers, Jean Viggers, Sharon C. Cheetham, Peter R. Guzzo	11
6	The neuropharmacology of ADHD drugs in vivo: Insights on efficacy and safety 2009 ·Neuropharmacology ·David J. Heal, Sharon C. Cheetham, Sharon L. Smith	157
7	The monoamine reuptake inhibitor BTS 74 398 fails to evoke established dyskinesia but does not synergise with levodopa in MPTP‐treated primates 2004 ·Movement Disorders ·(unknown), Lance A. Smith, Michael S. Jackson, Sharon C. Cheetham, Peter Jenner	17
8	Dopamine, but Not Norepinephrine or Serotonin, Reuptake Inhibition Reverses Motor Deficits in 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Treated Primates 2002 ·Journal of Pharmacology and Experimental Therapeutics ·(unknown), Lance A. Smith, Michael S. Jackson, Sharon C. Cheetham, Peter Jenner	58
9	Sibutramine does not decrease the number of 5-HT re-uptake sites in rat brain and, like fluoxetine, protects against the deficits produced by dexfenfluramine 2000 ·Neuropharmacology ·Sharon C. Cheetham, Jean Viggers, (unknown), David J. Heal	6
10	The effects of the peptide-coupling agent, EEDQ, on 5-HT2A receptor binding and function in rat frontal cortex 1999 ·Neuropharmacology ·Christine Kettle, Sharon C. Cheetham, Keith F. Martin, M.R. Prow, D.J. Heal	15
11	5-HT1A Receptor binding sites in post-mortem brain samples from depressed suicides and controls 1997 ·Journal of Affective Disorders ·Sandra Lowther, Freddy De Paermentier, Sharon C. Cheetham, M. Rufus Crompton, Cornelius Katona, Roger W. Horton	90
12	Reduced dopamine turnover in the basal ganglia of depressed suicides 1997 ·Brain Research ·(unknown), Sharon C. Cheetham, Sandra Lowther, Cornelius Katona, M. Rufus Crompton, Roger W. Horton	78
13	Dopamine D2 receptors: A potential pharmacological target for nomifensine and tranylcypromine but not other antidepressant treatments 1995 ·Pharmacology Biochemistry and Behavior ·Keith F. Martin, Ian Phillips, Sharon C. Cheetham, David J. Heal	22
14	[3H]Paroxetine binding in rat frontal cortex strongly correlates with [3H]5-HT uptake: Effect of administration of various antidepressant treatments 1993 ·Neuropharmacology ·Sharon C. Cheetham, Jean Viggers, Nigel K.H. Slater, David J. Heal, W. R. Buckett	109
15	Evidence that RU 24969‐induced locomotor activity in C57/B1/6 mice is specifically mediated by the 5‐HT_1B receptor 1993 ·British Journal of Pharmacology ·Sharon C. Cheetham, David J. Heal	57
16	Brainβ-adrenoceptor binding sites in depressed suicide victims: effects of antidepressant treatment 1991 ·Psychopharmacology ·Freddy De Paermentier, Sharon C. Cheetham, M. Rufus Crompton, Cornelius Katona, Roger W. Horton	31
17	Brain 5-HT uptake sites, labelled with [3H]paroxetine, in antidepressant-free depressed suicides 1990 ·Brain Research ·Kevin M. Lawrence, Freddy De Paermentier, Sharon C. Cheetham, M. Rufus Crompton, Cornelius Katona, Roger W. Horton	71
18	[3H]5-hydroxytryptamine binding sites in postmortem human brain 1989 ·Neuropharmacology ·Sharon C. Cheetham, (unknown), Roger W. Horton	4
19	[3H]5-HT binding in post-mortem human cerebral cortex: methodological considerations 1989 ·Journal of Neural Transmission ·Sharon C. Cheetham, Roger W. Horton	4
20	Brain GABAB binding sites in depressed suicide victims 1988 ·Psychiatry Research ·(unknown), Sharon C. Cheetham, M. Rufus Crompton, Cornelius Katona, Roger W. Horton	45

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact